Cancer Centre
Unlocking the key to leukaemia progression in kids
Team
Reports and Findings
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.
Children's Cancers Published research Leukaemia Translational ResearchSurvival Outcomes of Children with Relapsed or Refractory Myeloid Leukemia Associated with Down syndrome
Children with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population.
Children's Cancers Published research Leukaemia Translational Research Child disabilityAcute Leukaemia of Ambiguous Lineage Presenting as a Focal Bone Lesion: a Case Report
Acute leukaemia is the most common childhood malignancy. Almost all cases are classified as acute lymphoblastic leukaemia or acute myeloid leukaemia. Acute leukaemia of ambiguous lineage (ALAL) is a rare form of acute leukaemia that cannot be classified by a single lineage. Like other acute leukaemias, ALAL typically presents with nonspecific symptoms such as fatigue, fever, or bleeding.
Children's Cancers Brain Tumour Research Leukaemia Translational ResearchCardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi consensus
Cardio-oncology is a new multidisciplinary area of expertise that seeks to pre-emptively and proactively address cardiac complications that emerge during and following cancer therapy. Modern therapies including molecular targeted therapy and immunotherapy have broadened the agents that can cause cardiac sequelae, often with complications arising within days to weeks of therapy.
Children's Cancers Published research Leukaemia Translational Research